

AKT-Independent Signaling Downstream of Oncogenic *PIK3CA* Mutations in Human Cancer

Krishna M. Vasudevan,^{1,2,3,13} David A. Barbie,^{1,5,12,13} Michael A. Davies,^{7,13} Rosalia Rabinovsky,^{1,2,3} Chontelle J. McNear,^{1,2} Jessica J. Kim,^{1,2} Bryan T. Hennessy,⁷ Hsiuyi Tseng,¹ Panisa Pochanard,¹ So Young Kim,^{1,2,5} Ian F. Dunn,^{1,2,3,4,5} Anna C. Schinzel,^{1,2,5} Peter Sandy,⁸ Sebastian Hoersch,⁸ Qing Sheng,^{1,3,4} Piyush B. Gupta,⁵ Jesse S. Boehm,⁵ Jan H. Reiling,⁹ Serena Silver,⁵ Yiling Lu,⁷ Katherine Stemke-Hale,⁷ Bhaskar Dutta,⁷ Corwin Joy,⁷ Aysegul A. Sahin,⁷ Ana Maria Gonzalez-Angulo,⁷ Ana Lluch,¹⁰ Lucia E. Rameh,¹¹ Tyler Jacks,⁸ David E. Root,⁵ Eric S. Lander,⁵ Gordon B. Mills,⁷ William C. Hahn,^{1,2,3,4,5} William R. Sellers,^{1,6} and Levi A. Garraway^{1,2,3,5,*}

¹Department of Medical Oncology, Dana-Farber Cancer Institute

²Center for Cancer Genome Discovery, Dana-Farber Cancer Institute

³Department of Medicine, Brigham and Women's Hospital

⁴Department of Neurosurgery, Brigham and Women's Hospital

Harvard Medical School, Boston, MA 02115, USA

⁵The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA

⁶Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA

⁷Department of Systems Biology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA

⁸Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA

⁹Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA

¹⁰Universidad de Valencia Clinic Hospital, 46010 Valencia, Spain

¹¹Boston Biomedical Research Institute, 64 Grove Street, Watertown, MA 02472, USA

¹²Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA

¹³These authors contributed equally to this work

*Correspondence: levi_garraway@dfci.harvard.edu

DOI 10.1016/j.ccr.2009.04.012

SUMMARY

Dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. *PTEN* tumor suppressor or *PIK3CA* oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many *PIK3CA* mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in *PIK3CA* mutant cancer cells. Thus, PI3K may promote cancer through both AKT-dependent and AKT-independent mechanisms. Knowledge of differential PI3K/PDK1 signaling could inform rational therapeutics in cancers harboring *PIK3CA* mutations.

INTRODUCTION

Aberrant phosphatidylinositol 3-kinase (PI3K) signaling occurs commonly in cancer (Vivanco and Sawyers, 2002). Upon activa-

tion at the plasma membrane by receptor tyrosine kinases or RAS proteins (Engelman et al., 2006), PI3Ks phosphorylate the D3 position on membrane phosphatidylinositides, thereby recruiting and activating proteins that contain a pleckstrin homology (PH) or

SIGNIFICANCE

Genetic alterations targeting the PI3K pathway are highly prevalent in many human cancers. For example, gain-of-function mutations in *PIK3CA*, which encodes a key enzymatic subunit of PI3K, occur frequently in breast, colon, and endometrial cancers, among others. Downstream activation of the AKT kinase is regarded as the dominant tumor-promoting mechanism enacted by PI3K signaling. However, this study shows that AKT signaling is markedly diminished in many cancer cell lines and human breast tumors harboring *PIK3CA* mutations. Instead, these cells elaborate a signaling pathway involving the PI3K effector PDK1 and its downstream substrate SGK3. These findings may have important implications for PI3K signaling and the development of rational therapeutics against this key cancer pathway.

other lipid-binding domain. This activity is antagonized by the PTEN tumor suppressor protein. The serine/threonine kinase AKT/PKB (AKT), upon activation by PDK1 and the TORC2 complex (Alessi et al., 1997; Sarbassov et al., 2005; Stephens et al., 1998), is believed to transduce the major downstream PI3K signal in cancer. AKT regulates cell growth and survival pathways by phosphorylating substrates such as GSK3, Forkhead transcription factors, and the TSC2 tumor suppressor protein (Vivanco and Sawyers, 2002).

Both *PTEN* and *PIK3CA*, which encodes the catalytic (p110 α) subunit of PI3K, are frequently mutated across many human cancers. The most common tumor-associated *PIK3CA* mutations (>80% of cases) involve either the helical domain (exon 9; e.g., E542K and E545K) or the kinase domain (exon 20; e.g., H1047R) of p110 α (Samuels et al., 2004, 2005). Inactivating *PTEN* mutations occur commonly in prostate cancer, endometrial cancer, and glioblastoma, among others (Vivanco and Sawyers, 2002). Rare activating somatic mutations of *AKT1* have also been described in cancer (Carpten et al., 2007).

Although inactivating *PTEN* mutations and activating *PIK3CA* mutations both augment AKT signaling in several experimental systems (Kang et al., 2005; Nakamura et al., 2000), it is not clear whether such genetic alterations are functionally redundant in vivo. For example, in endometrial cancers *PIK3CA* and *PTEN* mutations often co-occur (Oda et al., 2005), suggesting that they may have distinct roles. Similarly, *PIK3CA* mutations may be seen in breast cancers with low PTEN levels, and AKT phosphorylation correlates poorly with *PIK3CA* mutation in this malignancy (Stemke-Hale et al., 2008). In addition, while PTEN loss has been associated with adverse clinical outcome in breast cancer (Depowski et al., 2001), the prognosis associated with *PIK3CA* alterations may depend on the type of mutation. In one study, for example, helical mutations correlated with poorer prognosis than kinase-domain mutations (Barbareschi et al., 2007). Thus, as observed for RAS and RAF oncoproteins in the MAP kinase cascade (Solit et al., 2006), the position of somatic alterations within the PI3K pathway (or *PIK3CA* itself) may influence the mechanisms and, by extension, the functional output of oncogenic pathway deregulation. Here, we used a phosphoprotein profiling and functional genetic approach to characterize signaling mechanisms downstream of PI3K in *PIK3CA* mutant cancer cells.

RESULTS

PIK3CA Mutant Cancer Cells Frequently Show Diminished AKT Signaling

To determine whether somatic PTEN loss and *PIK3CA* activation lead to the same signaling consequences in cancer, we interrogated phosphoprotein profiles associated with distinct alterations affecting the PI3K pathway by reverse-phase protein array (RPPA) analysis (Tibes et al., 2006). Analysis of the quantitative protein expression signal from PTEN and phosphorylated AKT (p-AKT) in the NCI60 cancer cell line collection (Stinson et al., 1992) identified 12 lines with low or absent PTEN protein (Figure 1A). As expected (Nakamura et al., 2000), all cell lines with low PTEN (PTEN null) exhibited enhanced AKT phosphorylation at both serine 473 and threonine 308 (Figures 1B and 1C; $p < 0.001$ for both p-AKT sites).

We then analyzed the relationship between the *PIK3CA* mutations and levels of p-AKT. Previous sequencing studies identified seven NCI60 cell lines (spanning four tumor types) that harbor *PIK3CA* mutations; three lines with kinase-domain mutations (SK-OV-3, HCT-116, and T-47D), and four with helical mutations (HT-29, HCT-15, MCF-7, and NCI-H460) (<http://www.sanger.ac.uk/genetics/CGP/cosmic/> and confirmed with the lines used here). In contrast to the PTEN null setting, NCI60 lines with activating *PIK3CA* mutations contained much lower p-AKT RPPA signals when compared to PTEN null cell lines, irrespective of tumor type ($p < 0.001$ for Ser473 and $p = 0.002$ for Thr308; Figures 1B and 1C).

As *PIK3CA* mutations were relatively uncommon in the NCI60 panel, we confirmed this observation in 51 human breast cancer cell lines (Neve et al., 2006) (see Figure S1 available online). We also observed similar RPPA patterns by hierarchical clustering of PTEN and p-AKT RPPA signals in 64 hormone receptor-positive breast tumor samples (Figure S2). Whereas elevated p-AKT at Ser473 and Thr308 correlated inversely with PTEN levels in all cases, many *PIK3CA* mutant cell lines and breast tumors contained low p-AKT levels (Figures S1 and S2). In these experiments, reduced p-AKT expression was particularly apparent (though not universal) in the setting of helical (e.g., E542K/E545K) *PIK3CA* mutations (*PIK3CA*^{helical}) (Figures S1B, S1C, and S2B), although multiple cell lines and tumors with kinase domain (e.g., H1047R) mutations (*PIK3CA*^{kinase}) also showed low p-AKT (Figures 1B and 1C and Figures S1B, S1C, and S2A). These findings, together with previous studies of human breast tumors (Stemke-Hale et al., 2008), raised the possibility that PTEN loss and *PIK3CA* mutation might have different effects on AKT signaling.

To examine AKT pathway activation in more detail, we performed immunoblot analyses on selected cancer cell lines that lack *PTEN* or express activating *PIK3CA* alleles. Strikingly, p-AKT at both Ser473 and Thr308 was markedly diminished in the four *PIK3CA*^{helical} cell lines examined, as shown in Figure 1D. AKT phosphorylation in *PIK3CA*^{kinase} cells was more variable, approaching the levels observed in PTEN null cells in some cases (e.g., BT-20, MDA-MB-453, and HCC1954; Figure 1D), while virtually undetectable in others (e.g., HCT-116; Figure S3A). For most ensuing experiments, we considered MCF-7, HCT-15, and SW948 as representative *PIK3CA* mutant cells with low p-AKT; T47D and HCC1954 as representative *PIK3CA* mutant cell lines with elevated p-AKT; and 786-0 as a representative PTEN null cell line. Additional studies under serum-starved conditions showed that the level of AKT phosphorylation in several *PIK3CA* mutant cancer cell lines was comparable to a nontransformed setting (e.g., MCF-10A and MCF-12A cells; Figure S3B). Thus, many *PIK3CA* mutant cancer cells exhibited unexpectedly low AKT signaling.

We considered the possibility that the reduced AKT phosphorylation could reflect down-modulation through known feedback regulatory mechanisms (Haruta et al., 2000; O'Reilly et al., 2006). In this case, downstream effectors might be active even though p-AKT levels are suppressed. To test this, we examined RPPA data corresponding to the AKT substrates GSK3 β and TSC2 in the NCI60 panel. Phosphorylation of both substrates was reduced in *PIK3CA* mutant cells compared to *PTEN* null cells (Figures 1E and 1F). Immunoblot studies confirmed a tight




Figure 1. PTEN Null and *PIK3CA* Mutant Cancer Cells Show Different Steady-State AKT Pathway Activation Patterns

(A–C) Quantitative RPPA protein expression levels were determined in NCI60 cells showing loss of PTEN (PTEN null) (green), helical *PIK3CA* mutation (Helical) (red), kinase *PIK3CA* mutation (Kinase) (blue), or a wild-type pattern for PTEN and *PIK3CA* (WT/WT) (gray). Relative protein levels of PTEN (A), p-AKT (Ser473) (B), and p-AKT (Thr308) (C) are shown. The diminished PTEN protein levels in PTEN null cells are statistically significant ($p < 0.001$ when compared to both *PIK3CA* mutant and wild-type cells). PTEN null cell lines have higher p-AKT (Ser473) and p-AKT (Thr308) levels than *PIK3CA* mutant lines ($p = 0.0006$ and $p = 0.002$, respectively) or WT/WT lines ($p = 0.0002$ and $p = 0.0003$, respectively). The *PIK3CA* mutant cell lines do not differ significantly from the WT/WT cell lines ($p = 0.62$ and $p = 0.25$, respectively, for each p-AKT residue).

(D) Immunoblot analysis of AKT phosphorylation (p-AKT) at Ser473 and Thr308 across a panel of PTEN null or *PIK3CA* mutant cancer cell lines.

(E and F) Quantitative RPPA levels were determined for p-GSK3- α/β (E) and p-Tuberin (F). PTEN null cells show higher phosphorylation of both AKT substrates than *PIK3CA* mutant cells ($p = 0.003$ and $p = 0.002$, respectively) and WT/WT lines ($p = 0.003$ and 0.001 , respectively).

(G) Fluorescence microscopy of transient GFP-FOXO1 expression in PTEN null or *PIK3CA* mutant cancer cell lines. Lines with high or low p-AKT are indicated. Scale bars, 30 μm .

correlation between p-GSK3 β and p-AKT (Figure S3C). Furthermore, we observed no correlation between phosphorylation or activity of p70S6 kinase (a known modulator of the feedback loop [Haruta et al., 2000; O'Reilly et al., 2006]) and p-AKT levels in *PIK3CA* mutant cells (M.A.D. and R.R., unpublished data). Thus, decreased p-AKT correlated with reduced substrate phosphorylation, suggesting that feedback loops do not fully explain the AKT signaling dynamics in these *PIK3CA* mutant cells.

We also assessed functional AKT signaling by examining localization of the Forkhead transcription factor (FOXO), a direct AKT substrate, using a GFP-FOXO1 fusion construct (Brunet et al., 1999; Nakamura et al., 2000). Activated AKT phosphorylates FOXO transcription factors and prevents their nuclear entry (Brunet et al., 1999). In these experiments, GFP-FOXO1 localized to the cytoplasm in PTEN null cells (786-0 and LNCaP; Figure 1G) and in *PIK3CA* mutant cells with robust p-AKT expression (T47D and HCC1954; Figure 1G), consistent with downstream pathway activation (Nakamura et al., 2000). However, *PIK3CA* mutant cells with low p-AKT (MCF-7, HCT-15, HCT-116, and SW-948) exhibited nuclear GFP-FOXO1, comparable to cells with a “wild-type” PI3K pathway (ACHN and DU-145; Figure 1G) and to the effects of a GFP-FOXO1-A3 construct resistant to AKT-mediated cytoplasmic localization (Figure S3D). Together with the RPPA and immunoblotting data, these results provided strong evidence that AKT signaling is often diminished in *PIK3CA* mutant cancers.

***PIK3CA* Mutant Cells with Low p-AKT Show Reduced Dependence on AKT for Tumorigenicity**

We next determined whether AKT-dependent signaling is required for tumorigenicity in *PIK3CA* mutant cells. Here, we examined anchorage-independent growth on soft agar following lentiviral RNAi knockdown (Moffat et al., 2006). Since many cancer cells express multiple AKT isoforms (Figure S5A), we also tested a dominant-negative AKT construct (Dudek et al., 1997), which inhibits all AKT variants (dnAKT). Suppression of *AKT1* reduced soft agar growth in PTEN null cells (786-0) and *PIK3CA* mutant cells with high p-AKT (T47D and HCC1954; Figure 2A and Figure S4A). In contrast, neither *AKT1* knockdown nor dominant-negative inhibition had any discernible effect on anchorage-independent growth in *PIK3CA* mutant cell lines with low p-AKT (MCF-7, SW948, and HCT-15; Figures 2A and 2C and Figure S4B). Similarly, combined knockdown of *AKT1* and *AKT2* (Figure S5B) had only minimal effects on MCF-7 cell growth (*PIK3CA* mutant, low p-AKT; Figures S5C and S5D). In contrast, combined *AKT1/2* knockdown was highly deleterious to PTEN null cells with elevated p-AKT (786-0 cells; Figure S5D and data not shown).

To confirm dependency on the PI3K pathway in *PIK3CA* mutant cells, we performed small hairpin RNA (shRNA)-mediated knockdown of *PIK3CA* expression. As expected, *PIK3CA* knockdown markedly reduced the anchorage-independent growth of several exemplary *PIK3CA* mutant cell lines, regardless of




Figure 2. PTEN Null and *PIK3CA* Mutant Cells Show Differential Dependency on AKT for Cell Viability and Anchorage-Independent Growth

(A and B) Anchorage-independent growth following lentiviral RNAi knockdown of *AKT1* (A) or *PIK3CA* (B) in PTEN null (786-0), *PIK3CA* mutant cells with low p-AKT (MCF-7 and SW-948), and *PIK3CA* mutant cells with high p-AKT (T47D). For each gene, knockdown efficacy of two independent shRNAs was measured by western blot (left) and colony formation in soft agar was enumerated (right). Data are mean \pm SD; each experiment was performed in triplicate.

(C) Expression of HA-tagged dominant-negative AKT (DN-AKT) in PTEN null (786-0) or *PIK3CA* mutant cells with low p-AKT (MCF-7 and HCT15). Immunoblot analysis for DN-AKT expression (top) and effects of DN-AKT on anchorage-independent growth (bottom) are shown.

results suggested that the diminutive AKT signaling in some *PIK3CA* mutant contexts may result from its inefficient translocation to the plasma membrane.

We next examined the abundance of PI3K-derived phosphatidylinositol products in relation to the mode of PI3K activation (Vanhaesebroeck et al., 2001). Using a monoclonal antibody recognizing PtdIns(3,4,5)P₃ (Figure S6B), we found that PTEN null cells (786-0) and *PIK3CA* mutant cells with elevated p-AKT (T47D and HCC1954) showed robust membrane staining for this phospholipid (Figure 3A, bottom), whereas *PIK3CA* mutant cells with low p-AKT

(MCF-7 and SW-948) showed reduced PtdIns(3,4,5)P₃ (Figure 3A, bottom). The fluorescence intensity of this antibody was suppressed following incubation with the PI3K inhibitor LY-294002 (Figure S6B), suggesting a specific recognition of PI3K-derived phosphatidylinositol products. To confirm these experiments, we measured phosphatidylinositol levels directly by ³[H]-inositol-based metabolic labeling studies. Both PI(3,4,5)P₃ and PI(3,4)P₂ were significantly reduced in *PIK3CA* mutant cell lines with low p-AKT compared to *PIK3CA* mutant cells with high p-AKT (Figures 3B and 3C). Together, these results suggested that reduced levels of key PI3K phosphatidylinositol products may impair AKT membrane localization (and subsequent activation) in some *PIK3CA* mutant cells.

AKT Membrane Localization Correlates with 3'-Phosphatidylinositol Levels in *PIK3CA* Mutant Cells

Next, we sought to understand the mechanism whereby AKT fails to undergo robust activation despite the presence of oncogenic *PIK3CA* mutations. To become activated, AKT is recruited to the plasma membrane through its PH domain by PI3K-derived phosphatidylinositols. Therefore, we examined the cellular localization of AKT in PTEN null or *PIK3CA* mutant cells. Transient transfection of a construct expressing the AKT PH domain fused to green fluorescent protein (PH-AKT-GFP; Varnai and Balla, 1998; Watton and Downward, 1999) under serum-starved conditions resulted in GFP membrane localization in PTEN null cells (786-0) and *PIK3CA* mutant cells with elevated p-AKT (HCC1954 and T47D), but not in *PIK3CA* mutant cells with low p-AKT (MCF-7 and SW-948; Figure 3A, top). Immunofluorescence studies of endogenous AKT1 yielded similar results (Figure S6A). These

(MCF-7 and SW-948) showed reduced PtdIns(3,4,5)P₃ (Figure 3A, bottom). The fluorescence intensity of this antibody was suppressed following incubation with the PI3K inhibitor LY-294002 (Figure S6B), suggesting a specific recognition of PI3K-derived phosphatidylinositol products. To confirm these experiments, we measured phosphatidylinositol levels directly by ³[H]-inositol-based metabolic labeling studies. Both PI(3,4,5)P₃ and PI(3,4)P₂ were significantly reduced in *PIK3CA* mutant cell lines with low p-AKT compared to *PIK3CA* mutant cells with high p-AKT (Figures 3B and 3C). Together, these results suggested that reduced levels of key PI3K phosphatidylinositol products may impair AKT membrane localization (and subsequent activation) in some *PIK3CA* mutant cells.

PTEN Regulates AKT Activation in *PIK3CA* Mutant Cells

The direct correlation between AKT phosphorylation, membrane localization, and PI3K phospholipid products also suggested that PTEN activity might suppress AKT activation in some *PIK3CA* mutant cells by constraining phosphatidylinositol accumulation. This notion was buttressed by our observations that most *PIK3CA* mutant cells with low p-AKT robustly expressed wild-type PTEN (Figure 1D and Figure S2B). To test this, we performed shRNA knockdown of PTEN in PI3K pathway wild-type cells (DU-145) or *PIK3CA* mutant cells with low p-AKT (MCF-7) and measured p-AKT levels. As expected, AKT phosphorylation at both Ser473 and Thr308 was induced upon PTEN knockdown (Figure 3D), suggesting that PTEN may play a dominant role






Figure 3. AKT Subcellular Localization, Phosphatidylinositol Studies, and PTEN Regulation in *PIK3CA* Mutant Cells

(A) Immunofluorescence studies of transient PH-AKT-GFP expression (top) and PI(3,4,5)P₃ levels (bottom) are shown for wild-type (DU145), PTEN null (786-0), *PIK3CA* mutant cells with low p-AKT (MCF-7 and SW-948), and *PIK3CA* mutant cells with high p-AKT (HCC1954 and T47D). Scale bars, 30 μm.

(B and C) Relative levels of PtdIns(3,4,5)P₃ (B) and PtdIns(3,4)P₂ (C) are shown in wild-type (DU145), PTEN null (786-0 and SF-539), *PIK3CA* mutant cells with low p-AKT (MCF-7, HCT-15, and SW-948), and *PIK3CA* mutant cells with high p-AKT (HCC1954, MDA-MB453, and T47D). Error bars represent standard deviations of the mean for each cell line group.

(D) Immunoblot analysis of AKT phosphorylation (p-AKT) at Ser473 and Thr308 following PTEN knockdown in wild-type (DU145) or *PIK3CA* mutant cells with low p-AKT (MCF-7).

in AKT regulation, even in the presence of oncogenic *PIK3CA* mutations.

PDK1 Is Highly Expressed and Required for Tumorigenicity in *PIK3CA* Mutant Cancer Cells

The pleckstrin-homology (PH) domain-containing kinase PDK1 is also recruited to cell membranes in response to PI3K activation and is independently required for PI3K-mediated transformation in several systems (Bayascas et al., 2005; Flynn et al., 2000; Zeng et al., 2002). To examine PDK1 activity in relation

both *PIK3CA*^{helical} and *PIK3CA*^{kinase} mutations were observed in this tumor panel (p = 0.01 compared to wild-type tumors for each mutation; Figure 4A), confirming robust PDK1 expression and activation in the setting of *PIK3CA* mutation in vivo. To determine if this phenomenon was manifest in vitro, we also examined activated PDK1 levels in our panel of PTEN null or *PIK3CA* mutant cell lines. Consistent with the breast tumor findings, all *PIK3CA* mutant cell lines examined showed robust p-PDK1 levels, regardless of mutation type and p-AKT levels (Figures 4B and 4C), although p-PDK1 was not affected by treatment




Figure 4. PDK1-Dependent Signaling and Tumorigenicity in *PIK3CA* Mutant Cells

(A) RPPA expression of p-PDK1 (S241) in 224 hormone receptor-positive human breast tumors. Samples were grouped according to the type of *PIK3CA* mutation (Helical or Kinase) or “no mutation.”

(B) Immunoblotting studies of p-PDK1 (S241) and total PDK1 are shown in wild-type (MALME and DU145), *PIK3CA*-mutant (high pAKT: BT-20, HCC1954, and MDA-MB-453; low pAKT: MCF-7, SW-948, and HCT-15), and PTEN null cells (786-0 and SF-539).

(C) Quantification of the immunoblot signal as average intensities + SD are shown for the cell lines in (B).

(D and E) Anchorage-independent growth following lentiviral RNAi knockdown of PDK1 in *PIK3CA* mutant cells with low p-AKT (MCF-7) (D) or high p-AKT (T47D) (E). Knockdown efficacy of two independent shRNAs was measured by western blot (left) and colony formation in soft agar was enumerated (right). Data are mean ± SD; each experiment was performed in triplicate.




Figure 5. PI3K-Dependent Membrane Association of PDK1 in *PIK3CA* Mutant Cells

(A) Fluorescence microscopy of transient PH-PDK1-GFP expression is shown for serum-starved wild-type (DU145), PTEN null (786-0), *PIK3CA* mutant cells with low p-AKT (MCF-7 and SW-948), and *PIK3CA* mutant cells with high p-AKT (HCC1954 and T47D). Scale bars, 30 μ M. (B) Immunoblotting studies of cytosolic (Cy) and membrane (M) fractions prepared from serum-starved wild-type (ACHN), PTEN null (786-0), or *PIK3CA* mutant cells (MCF-7, HCT-15, and HCC-1954) are shown. (C) Immunoblotting studies of cytosolic (Cy) and membrane (M) fractions prepared following shRNA knockdown of p110 α (sh-*PIK3CA*) or control (sh-GFP) in serum-starved MCF-7 cells. (For B and C, antibodies recognizing p-AKT [S473], AKT1, p-PDK1 [S241], PDK1, Cadherin, and GAPDH were used.)

(D) Quantification of the immunoblot signal is shown as a normalized ratio of membrane/cytosolic PDK1 (total) for the blot in (C).

membrane localization was PI3K dependent (Figure 5A). These results indicated that PI3K-driven PDK1 signaling remained robust even when AKT-dependent signaling was reduced.

We also studied PDK1 membrane localization by a more sensitive approach involving separation of membrane and cytosolic fractions under serum-starved conditions. Endogenous p-AKT, total AKT, p-PDK1 (Ser241), and total PDK1 were measured in each fraction. In PTEN null cells (786-0) and *PIK3CA* mutant cells with high p-AKT (HCC1954), both p-AKT and p-PDK1

were present in the membrane fractions (Figure 5B). Membrane p-PDK1 and total PDK1 were also detectable in *PIK3CA* mutant cells with low p-AKT (MCF-7, HCT15, and SW-948); however, membrane p-AKT was not identified (Figures 5B and Figure S7D). We then examined PDK1 localization following lentiviral RNAi knockdown of *PIK3CA*. Reduction of *PIK3CA* expression by two independent shRNAs resulted in a measurable decrease in membrane PDK1 in MCF-7 cells under serum-starved conditions (Figures 5C and 5D). These results lent additional credence to the notion that oncogenic p110 α regulates PDK1 membrane localization in *PIK3CA* mutant cancer cells, even when AKT signaling is diminished.

with LY-294002 (data not shown). Moreover, increased p-PDK1 was also linked significantly to *PI3KCA*^{helical} cells in a follow-up RPPA analysis of 51 breast cancer cell lines ($p = 0.03$ compared to wild-type cells; Figure S7B), despite the reduced p-AKT levels in this subset (Figures S1B and S1C). We then considered whether *PIK3CA* mutant cancer cells with low p-AKT remained dependent on PDK1 signaling. As expected, PDK1 knockdown strongly suppressed anchorage-independent growth in representative *PIK3CA*-mutant (MCF-7 and T47D) and PTEN null cells (786-0) (Figures 4D and 4E and Figure S7C), indicating a functional dependence on PDK1 in these cells. Thus, activated PDK1 is highly expressed and required for tumorigenicity in cancers harboring *PIK3CA* mutations.

PDK1 Shows PI3K-Dependent Membrane Localization in *PIK3CA* Mutant Cells

To study PDK1 activation in more detail, we performed immunofluorescence studies under serum-starved conditions following transfection of a construct expressing the PH domain of PDK1 fused to GFP (PH-PDK1-GFP). In contrast to the analogous experiments with PH-AKT-GFP above, PH-PDK1-GFP fluorescence accumulated at the plasma membrane in all PTEN null and *PIK3CA* mutant cell lines examined, regardless of p-AKT levels; but this membrane localization was less evident in PI3K pathway wild-type cells (Figure 5A). Moreover, membrane GFP fluorescence was reduced following treatment with LY-294002, suggesting that PH-PDK1

was present in the membrane fractions (Figure 5B). Membrane p-PDK1 and total PDK1 were also detectable in *PIK3CA* mutant cells with low p-AKT (MCF-7, HCT15, and SW-948); however, membrane p-AKT was not identified (Figures 5B and Figure S7D). We then examined PDK1 localization following lentiviral RNAi knockdown of *PIK3CA*. Reduction of *PIK3CA* expression by two independent shRNAs resulted in a measurable decrease in membrane PDK1 in MCF-7 cells under serum-starved conditions (Figures 5C and 5D). These results lent additional credence to the notion that oncogenic p110 α regulates PDK1 membrane localization in *PIK3CA* mutant cancer cells, even when AKT signaling is diminished.

SGK3 Is Required for AKT-Independent Viability in *PIK3CA* Mutant Cancer Cells

Next, we investigated possible mechanisms of PDK1-dependent, AKT-independent growth in *PIK3CA* mutant cells. Here, we screened six *PIK3CA* mutant human cancer cell lines (Table S1) using a lentiviral shRNA library targeting >1000 kinases, phosphatases, and other cancer genes (Boehm et al., 2007; Mofat et al., 2006), including 20 known PDK1 substrates (Table S2). We stratified the *PIK3CA* mutant lines into two groups based on p-AKT levels (three lines with elevated p-AKT and three with low p-AKT) and analyzed the top 10% of 120 shRNAs targeting PDK1 substrates whose effects on viability distinguished these two classes (illustrated schematically in Figure S8A). We considered




Figure 6. SGK3 Transduces an AKT-Independent Signal in *PIK3CA* Mutant Cells

(A) Distribution of 120 hairpins against 20 PDK1 substrates ranked according to the t test statistics applied to cell viability data. The tails of the curve represent hairpins that are selectively lethal in three *PIK3CA* mutant cell lines with high p-AKT (red) compared to three *PIK3CA* mutant cell lines with low p-AKT (blue). Multiple hairpins targeting *AKT1* or *SGK3* in the top 10% of hairpins distinguishing each class are indicated (circles).

(B and C) Cell viability data is shown for the top-scoring, knock-down-validated *AKT1* hairpins (B) and *SGK3* hairpins (C) in *PIK3CA* mutant lines with high versus low p-AKT levels.

(D) *SGK3* expression by immunoblot analysis (left) and cell viability (right) following lentiviral RNAi knockdown of *SGK3* in MCF-7 cells (*PIK3CA* mutant, low p-AKT). NS, nonspecific band. Scale bars, 500 μ m.

multiple *PIK3CA* mutant cells that lacked AKT activation showed a functional dependency on *SGK3*.

SGK3 Is Regulated by PDK1 and PI3K in *PIK3CA* Mutant Cancer Cells with Low p-AKT

To confirm PDK1-dependent modulation of *SGK3* and other known PDK1 substrates in *PIK3CA* mutant cells, we suppressed PDK1 expression and examined the resulting phosphorylation patterns (Vanhaesebroeck and Alessi, 2000). PDK1 knockdown substantially diminished phosphorylation of *SGK3* at Thr320 in MCF-7 cells (low p-AKT), but this effect was less apparent in T47D cells (elevated p-AKT) (Figure 7A). In contrast, protein kinase C beta/zeta phosphorylation was only minimally suppressed in MCF-7 and not at all in T47D (Figure 7A). PDK1 knockdown also reduced p-p70S6K(Thr229) and p-RSK(Ser227) in both cell lines; however, these PDK1 substrates were not

identified as selective dependencies in our RNAi analysis. As expected, PDK1 knockdown suppressed p-AKT (Thr308) in T47D cells (Figure 7A). Overall, these results provide biochemical evidence that *SGK3* contributes to an AKT-independent signal downstream of PDK1 in *PIK3CA* mutant cells, although the importance of additional PDK1 substrates and alternate effectors cannot be excluded.

As a gene a “hit” if two or more shRNAs against this gene suppressed viability with a B score less than -1 (see Experimental Procedures). Interestingly, only 1 of 20 PDK1 substrates met the aforementioned criteria in each *PIK3CA* mutant class. *AKT1* knockdown most strongly suppressed viability in *PIK3CA* mutant cells with high p-AKT, as expected (Figures 6A and 6B). Multiple *AKT2* hairpins also segregated within the top 10% of hairpins distinguishing the high p-AKT class (Figure S8A), though their absolute effects on cell viability were more modest, consistent with lower abundance of this AKT isoform in many cell types. The knock-down efficacy of multiple shAKT1 hairpins was confirmed by RT-PCR analysis and immunoblotting (Figure S8B). In contrast, hairpins targeting *SGK3* (serum/glucocorticoid regulated kinase 3; also known as *CISK*) most strongly suppressed viability in “low p-AKT” *PIK3CA* mutant cells (Figures 6A and 6C). *SGK3* is an intriguing candidate PDK1 effector; this kinase shares $\sim 50\%$ identity with AKT and contains a Phox homology (PX) domain, which binds phosphatidylinositols (Tessier and Woodgett, 2006). We confirmed knockdown efficacy of the two most potent shSGK3 hairpins by RT-PCR (Figure S8C) and immunoblotting (Figure 6D). *SGK3* knockdown strongly suppressed MCF-7 cell viability (Figure 6D), in marked contrast to the effects of AKT knockdown (Figures 2A and 2C, and Figures S5B–S5D). Thus,

we then tested whether *SGK3* activity is regulated by PI3K in the *PIK3CA* mutant context. The PX domain confers endosomal localization of *SGK3* through its avidity for phosphatidylinoside-3-phosphate, which is present at high levels on endosomal membranes. As expected, a construct expressing the *SGK3* PX domain fused to GFP localized to endosomes in all cancer cell lines examined (Figure S9A); this localization was unaffected by treatment with LY-294002 (Figure S9A). However, LY-294002 markedly reduced PDK1-dependent *SGK3*(T320) phosphorylation (Figures S9B and S9C) in *PIK3CA* mutant cells with low p-AKT (MCF-7 and HCT-15 cells; Figure 7B). Thus, *SGK3* activation but not endosomal localization is regulated by PI3K in the setting of *PIK3CA* mutation.

Next, we determined the extent to which *SGK3* exhibits PDK1-dependent phosphorylation in cancer cells and its relation to *PTEN* or *PIK3CA* mutation. Although p-SGK3(T320) was undetectable in nontransformed cells (MCF-10A and MCF-12A cells;




Figure 7. Immunoblot Analyses of PDK1-Dependent SGK3 Phosphorylation

(A) Immunoblot analysis of MCF-7 (*PIK3CA* mutant, low p-AKT) and T47D cells (*PIK3CA* mutant, high p-AKT) stably expressing shRNAs against GFP (control) or PDK1. Antibodies recognizing p-AKT (T308), AKT1, p-SGK3 (T320), SGK3, p-PKC ζ (T410), PKC ζ, p-RSK (S227), RSK2, p-p70 S6 kinase (T229), p70 S6 kinase, and actin were used.

(B) Immunoblot analysis of SGK3 phosphorylation at Thr320 (p-SGK3 [T320]) in the absence or presence of LY294002 is shown for MCF-7 and HCT-15 cells (*PIK3CA* mutant, low p-AKT).

(C) Immunoblot analysis of SGK3 phosphorylation (p-SGK3 [T320]) across a panel of PI3K pathway wild-type, PTEN null, or *PIK3CA* mutant cancer cell lines. Nontransformed lines (MCF-10A and MCF-12A) are included as negative controls. NS, nonspecific band.

Figure 7C). This phosphorylation event was evident in multiple cancer cell lines, including most *PIK3CA* mutant cells examined (Figure 7C). Furthermore, only SGK3, and not SGK1 or SGK2, was consistently expressed across all relevant *PIK3CA* mutant cell lines in our panel (Figure S9D). Taken together, these results suggest that SGK3 activation may be a characteristic of many cancers independent of AKT signaling.

DISCUSSION

Aberrant PI3K signaling has been studied extensively in cancer. This study provides evidence that *PIK3CA* mutations may contribute to tumorigenicity through both AKT-dependent and AKT-independent mechanisms. In the absence of AKT activation, PDK1 may transmit an alternative signal that engages downstream substrates such as SGK3 in *PIK3CA* mutant cancer cells. This study thereby nominates both PDK1 and SGK3 as key oncogenic effectors downstream of activating *PIK3CA* mutations.

Our AKT signaling results differ from studies in which mutant *PIK3CA* was expressed ectopically in cell culture/chick embryo models (Isakoff et al., 2005; Kang et al., 2005; Zhao et al., 2005)

or introduced by knockin methods into immortalized breast epithelial cells (Gustin et al., 2009). On the other hand, multiple experimental lines of evidence presented herein suggest that steady-state AKT signaling is reduced in many malignant contexts where *PIK3CA* mutations are present in situ. Moreover, the AKT and PDK1 activation patterns that we observe are consistent across many human cell lines and clinical breast tumor specimens, in line with published observations (Stemke-Hale et al., 2008). Of course, we cannot exclude the possibility that AKT signaling operates at low levels in some *PIK3CA* mutant cancers, even when poorly detectable by conventional methods. However, our findings suggest that in some settings the functional “output” of *PIK3CA* mutations differs importantly from that of deregulated PI3K activity observed in PTEN null cells.

Studies that use selective small molecule AKT inhibitors may help clarify the nature of AKT dependency in *PIK3CA* mutant cancers. Consistent with our results, sensitivity in vitro to inhibition by small molecule allosteric AKT1/2 inhibitors has been correlated strongly with AKT phosphorylation in human cancer cell lines (She et al., 2008). In the study by She et al. (2008), p-AKT was detectable in MCF7 cells and suppressed by an AKT inhibitor. Nonetheless, MCF-7 cells exhibited an attenuated sensitivity to pharmacologic AKT1/2 inhibition compared to several cancer cell lines with markedly elevated p-AKT levels (EC_{50} of $\sim 1 \mu\text{M}$; She et al., 2008). In our hands, AKT phosphorylation occasionally becomes detectable in MCF-7 cells after prolonged cultivation in vitro (e.g., ~ 1 year; K.M.V., unpublished data), suggesting that variances in cell culture conditions may influence p-AKT levels in some cases. Other studies have found *PIK3CA* mutant breast cancer cell lines to be generally more sensitive than *PIK3CA* mutant colon cancer cell lines to small molecule AKT inhibition, suggesting that cell lineage effects may also modulate this pharmacologic sensitivity. Altogether, these results endorse the notion that high p-AKT levels denote an AKT dependency in *PIK3CA* mutant cancer cells, while allowing for the possibility of AKT-independent signaling in settings where steady-state p-AKT is reduced.

Both “upstream” activation (through receptor tyrosine kinases, RAS signaling, or deficiencies in feedback regulation) and PTEN function provide important modes of PI3K regulation in cancer. Interestingly, several *PIK3CA* mutant breast cancer cell lines with high p-AKT examined herein have been shown to harbor either *ERBB2* overexpression/amplification (MDA-MB-453 and HCC-1954) (Blend et al., 2003; Miller et al., 1996) or high levels of activated EGFR (BT-20) (Zhang et al., 2002). Also, *PIK3CA* mutant cells and human breast tumors with low p-AKT tend to express wild-type PTEN and reduced 3'-phosphatidylinositides, whereas PTEN knockdown results in robust AKT phosphorylation. Thus, many *PIK3CA* mutant cancers that depend on AKT signaling may contain concomitant upstream signal deregulation (e.g., RTK/RAS activation or loss of feedback regulation) or PTEN deficiency (Oda et al., 2005). However, *PIK3CA* mutation by itself is neither necessary nor sufficient for full AKT pathway activation when it occurs in situ.

PIK3CA mutant cells exhibit robust p-PDK1 expression and membrane recruitment, regardless of AKT signaling. PDK1 exists in a constitutively active conformation that is not known to be further augmented by upstream signals (Casamayor et al., 1999). Oncogenic membrane recruitment of PDK1 appears

to depend at least partially on mutant *PIK3CA* (Figures 5A–5D). Differential membrane localization of PDK1 compared to AKT may relate in part to differing PH domain phosphatidylinositide binding affinities, since prior studies suggest that PDK1 may exhibit ~20-fold higher affinity for PI(3,4,5)P₃ than AKT (Stephens et al., 1998; Currie et al., 1999). PDK1 recruitment might also be aided by a kinase-independent function of mutant *PIK3CA*, such as stabilization of a RTK adaptor protein complex that permits phosphatidylinositol-independent PDK1 membrane localization. Toward this end, PDK1 was shown to bind the Grb14 adaptor protein in a PH domain-independent fashion (King and Newton, 2004). Thus, while AKT membrane localization (and subsequent activation) depends critically on elevated PI(3,4)P₂ and PI(3,4,5)P₃ levels, PDK1 localization may require a lesser degree of phosphatidylinositide accumulation.

PIK3CA mutant cancer cells with low AKT signaling exhibit a selective dependency on SGK3 for viability. The SGK family of AGC kinases shares more than 50% identity with the AKT kinase domain (Tessier and Woodgett, 2006). SGK proteins become direct PDK1 substrates as a result of C-terminal hydrophobic motif phosphorylation (Frodin et al., 2002; Sarbassov et al., 2005). Recent evidence suggests that hydrophobic motif phosphorylation within SGK is mediated by the TORC2 complex (Garcia-Martinez and Alessi, 2008) and that SGK proteins may function as critical mediators of cell growth downstream of ricin/TORC2 (Jones et al., 2009; Soukas et al., 2009). In accordance with previous findings, we show that PDK1-dependent SGK3 activation is under PI3K regulation in *PIK3CA* mutant cancer cells. The SGK3 PX domain exhibits a particular affinity for phosphatidylinositol 3' phosphate (Tessier and Woodgett, 2006), which localizes SGK3 to endosomal membranes (Figure S9A) (Virbasius et al., 2001). SGK3 recruits PDK1 to endosomes upon PI3K activation (Slagsvold et al., 2006). These phenomena raise the intriguing possibility that mutant p110 α may convey at least a portion of its oncogenic signal from or within endosomal compartments.

The precise oncogenic signal elaborated by SGK3 remains obscure, as few endosomal SGK3 substrates have been identified. The E3 ubiquitin ligase AIP4 was identified as an endosomal SGK3 substrate whose phosphorylation leads to stabilization of CXCR4 and promotes breast cancer metastasis (Slagsvold et al., 2006). The mammalian homolog of *Drosophila* Flightless I (FLI-I) is another putative SGK3 substrate (Xu et al., 2009). FLI-I phosphorylation may protect hematopoietic cells from death induced by cytokine withdrawal. Additional studies should inform whether AIP4 or FLI-I confer tumorigenic signals relevant to the *PIK3CA* mutant context.

Together, our observations offer a modified conceptual framework for oncogenic PI3K signaling. In the setting of PTEN deficiency, excess upstream activation, or defective feedback regulation, *PIK3CA* mutant cancers may elaborate sufficient membrane 3'-phosphatidylinositols to recruit both AKT and PDK1 to the plasma membrane. When this occurs, tumors will exhibit a robust (and usually "addictive") AKT-dependent signal. On the other hand, if PTEN function remains intact and upstream or feedback pathways are not fully dysregulated, *PIK3CA* mutations may transduce an AKT-independent signal that engages PDK1 and SGK3. Unlike AKT activation, which requires simultaneous and sufficient membrane recruitment of multiple proteins

following 3'-phosphatidylinositol synthesis, a moderate degree of PDK1 (endosomal) membrane localization may be all that is required to activate SGK3 in a PI3K-dependent manner.

In summary, this study has uncovered an AKT-independent signal operant within many *PIK3CA* mutant cancers. These results provide a mechanistic basis for recent observations suggesting biological differences between *PIK3CA* and PTEN mutation in human tumors (Saal et al., 2007; Stemke-Hale et al., 2008). Moreover, they suggest that inhibition of PI3K, PDK1, or downstream effectors may in some cases be more effective than inhibition of AKT. Several PI3K pathway inhibitors have entered clinical trials. Knowledge of the differential signaling pathways could thus inform the design of clinical trials in cancers defined by PI3K pathway mutations.

EXPERIMENTAL PROCEDURES

Lentiviral shRNAs and Plasmids

All lentiviral shRNA constructs were constructed in the pLKO.1puro vector (<http://www.broad.mit.edu/rnai/trc>). A list of lentiviral shRNAs used is shown in Table S3. The GFP-FOXO fusion construct was described previously (Nakamura et al., 2000). The plasmid pcDNA3-PH-AKT-GFP (Varnai and Balla, 1998) was a kind gift from Dr. Tamas Balla (National Institute of Health, Bethesda, MD).

Cell Culture

NCI60 cell lines were kindly provided by S. Holbeck (Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD). NCI60 cell lines were grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine, and harvested at 50%–80% confluence. Protein lysates were prepared from 51 human breast cancer cell lines using standard methods (see RPPA Analysis section below), and were provided by Dr. Joe Gray (Lawrence Berkeley National Laboratories, Berkeley, CA). 786-0, LNCaP, MDA-MB-361, SW-948, BT-20, HCC1954, T47D, MDA-MB-453, SK-OV3, HCT-15, DU145, ACHN, and MCF-7 cells were purchased from the American Type Culture Collection and cultured in media according to the suppliers' instructions. MCF-10A and MCF12A cells were provided by Dr. Kornelia Polyak (Dana-Farber Cancer Institute, Boston, MA). *PIK3CA* exons 9 and 20 were resequenced in all *PIK3CA*^{hetical} and *PIK3CA*^{kinase} cells to confirm the presence of the relevant mutations.

Breast Tumor Specimens

For the analysis of p-AKT and PTEN levels in vivo, 64 hormone receptor-positive breast tumor samples were obtained from patients with stages I–III adenocarcinoma and frozen in the Breast Tumor Tissue Bank at the M.D. Anderson Cancer Center (MDACC). For the subsequent studies of p-PDK1, an additional 160 tumors were analyzed from specimens that were obtained from the Breast Tissue Frozen Tumor Bank at MDACC and from Clinic Hospital (Valencia, Spain). All specimens were collected and studied under IRB-approved protocols at MDACC and Clinic Hospital through which informed consent was obtained or de-identified specimens were used. Pathologic assessment confirmed that each sample used was composed of at least 70% tumor cells. Tumors were lysed and protein extracted for RPPA as described below. DNA was extracted from the tumors and used for *PIK3CA* mutation detection or *PTEN* sequencing as described in Supplemental Experimental Procedures.

RPPA Analysis

RPPA assays were performed as described previously (Tibes et al., 2006) in Supplemental Experimental Procedures. Unsupervised hierarchical clustering was performed on mean-centered protein expression values using Cluster 2.1 software (<http://rana.lbl.gov/EisenSoftware.htm>). Results were visualized using Treeview software (<http://rana.lbl.gov/EisenSoftware.htm>). Correlations between protein levels were calculated using Microsoft Excel. Significance of these correlations was determined by canonical correlations using NCSS

Statistical and Power Analysis software. Differences between groups were assessed and visualized using MATLAB software.

Immunoblot Analysis, Transfections, and Fluorescence Microscopy

Antibodies recognizing total AKT, AKT1, p-AKT (S473 and T308), AKT2, AKT3, PTEN, p110 α , p-PDK1 (S241), Pan-Cadherin, GAPDH, GSK3 β , p-GSK3 β (Ser-9), and p-SGK3 (T320) (special order) were obtained from Cell Signaling Technology. An antibody recognizing PDK1 was obtained from BD Biosciences. p-PKC-zeta (T410), PKC-zeta, RSK2, and p70-S6 kinase antibodies were obtained from Santa Cruz Biotechnology. p-RSK (T227) and p-p70-S6 kinase antibodies were purchased from R&D Biosystems. SGK3 antibody was purchased from AbD Serotec. SGK1, SGK2, and β -actin antibodies were obtained from Sigma. Methodological details are provided in Supplemental Experimental Procedures.

Virus Production, Titration, and Infection

Lentiviruses were produced by transfection of 293 ϵ cells with the packaging plasmids encoding Δ 8.9 and VSV-G along with the lentiviral shRNA vector using Lipofectamine 2000 reagent, according to the manufacturer's instructions. To perform lentiviral infections, the target cells were plated at 40%–50% confluence and incubated overnight (16 hr). On the day of infections, the culture medium was replaced by the appropriately titered viral supernatant (1.5 ml/well) and incubated at 37°C for 10 hr; afterwards, the viral supernatant was replaced with fresh media. Forty-eight hours later, infected cell populations were selected in puromycin (2 μ g/ml): After 5 days of selection, shRNA knockdown efficiency was determined by western blot analysis for respective proteins using specific antibodies.

Anchorage-Independent Growth Assays

Methods are described in Supplemental Experimental Procedures.

Cell Proliferation Assay

Methods are described in Supplemental Experimental Procedures.

³H Lipid-Labeling Experiments

Cells were labeled with [³H]-inositol for 72 hr in inositol-free and serum-free medium. After labeling, cells were lysed in 1 M HCl. Lipids were extracted using chloroform/methanol (1:1, v/v) and deacylated as described (Serunian et al., 1991). Briefly, deacylated lipids were separated by anionic-exchange HPLC, detected by an online radiometric detector, and quantified by using the FLO-ONE analysis program (Packard). Each peak was identified by using in vitro-synthesized internal standard lipids. The counts present in each peak were normalized against the counts present in the phosphatidylinositol peak. P values were determined using a one-tailed Student's t test of the means of three *PIK3CA* mutant cell lines with low p-AKT (MCF-7, HCT-15, and SW-948) and three with high p-AKT (T-47D, HCC1954, and MDA-MB453).

RNAi Screen

Lentiviral shRNA infections were performed as described previously (Boehm et al., 2007; Moffat et al., 2006). Briefly, lentiviral infections were performed in high throughput using a subset of the TRC library containing approximately 5000 shRNA directed primarily against kinases and phosphatases (Boehm et al., 2007); data from known PDK1 substrates was extracted from this screen. On average, five unique shRNA were tested per gene for redundant coverage. Updated protocols for high throughput viral production and infection, as well as a database of hairpin designs are available online at <http://www.broad.mit.edu/mai/trc/lib>. Target cells were infected in 384 well plates in quadruplicate, with two "puromycin-plus" and two "puromycin-minus" replicates to assess for infection efficiency. Cell Titer Glo (Promega) was used to measure viability on average 6 days following lentiviral infection for most cell lines.

Data for each shRNA was normalized using the B score, an analog of the Z score that uses a two-way median polish to minimize row/column effects and normalization to the median absolute deviation to account for plate to plate (Malo et al., 2006). shRNA B score data was analyzed using the Comparative Marker Selection application suite in GenePattern (Gould et al., 2006). Distinguishing hairpins were ranked using either the t test statistic or the signal to noise ratio (measures of the difference in class mean viability scores, and the standard deviation across samples). Individual shRNA B score data for each

cell line was aligned and assembled into a .res file as an input into the Comparative Marker Selection application. Standard classification files were used to generate each of the class distinctions. shRNA viability data was ranked according to the t test statistic, and the top 10% shRNAs distinguishing the class of interest were filtered for genes with multiple hairpins to minimize potential off-target effects. In addition, at least one shRNA was required to promote significant viability loss across the class (mean B score less than -1) and one shRNA was required to yield a false discovery rate <25% for the comparison.

SUPPLEMENTAL DATA

Supplemental Data contain Supplemental Experimental Procedures, nine figures, and three tables and can be found with this article online at [http://www.cell.com/cancer-cell/supplemental/S1535-6108\(09\)00177-9](http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00177-9).

ACKNOWLEDGMENTS

We thank Erica Bauerlein for shRNA constructs; Len Pennacchio, Jan-Fang Cheng, Mandy Madiredio, Stefan Frohling, Claudia Scholl, and Raymond Wadlow for technical assistance; Tamas Balla for the PH-AKT GFP construct; Pablo Tamayo for statistical help; and Payman Amiri, Stephen Basham, Amit Dutt, Matthew Meyerson, David Livingston, David Sabatini, and members of the Garraway laboratory for helpful discussions. This work was supported by the Prostate Cancer Foundation, the Burroughs-Wellcome Fund (L.A.G.), the Department of Defense grant PC073284 (K.M.V.), the American Society for Clinical Oncology (M.A.D.); the Human Frontier Fellowship Organization (J.H.R.); the National Human Genome Research Institute (E.S.L.); the Susan Madden Fund (D.A.B.); the Starr Cancer Consortium 1A-11 (W.C.H.); and the National Institutes of Health grants T32CA09172-33 (D.A.B.), P50CA093459 (M.A.D.), R33CA128625, P01CA050661 (W.C.H.), P50CA112967, P30CA14051 (T.J.), R01CA085912 (W.R.S. and L.A.G.), and DP2OD002750-01 (L.A.G.). G.B.M. is a consultant for Amira Pharmaceuticals, Inc., Arcxis Biotechnologies, Catena Pharmaceuticals, Genentech, Inc., GlaxoSmithKline, Lpath Therapeutics, PTV Sciences, QLT, Inc., Semafore Pharmaceuticals, and Signal Pharmaceuticals. W.R.S. is an employee of Novartis, Inc. W.C.H. and L.A.G. are consultants for and received sponsored research support from Novartis, Inc.

Received: August 5, 2008

Revised: February 17, 2009

Accepted: April 27, 2009

Published: July 6, 2009

REFERENCES

- Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., and Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α . *Curr. Biol.* 7, 261–269.
- Barbareschi, M., Buttitta, F., Felicioni, L., Cotrupi, S., Barassi, F., Del Grammastro, M., Ferro, A., Dalla Palma, P., Galligioni, E., and Marchetti, A. (2007). Different prognostic roles of mutations in the helical and kinase domains of the *PIK3CA* gene in breast carcinomas. *Clin. Cancer Res.* 13, 6064–6069.
- Bayascas, J.R., Leslie, N.R., Parsons, R., Fleming, S., and Alessi, D.R. (2005). Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. *Curr. Biol.* 15, 1839–1846.
- Blend, M.J., Stastny, J.J., Swanson, S.M., and Brechbiel, M.W. (2003). Labeling anti-HER2/neu monoclonal antibodies with ¹¹¹In and ⁹⁰Y using a bifunctional DTPA chelating agent. *Cancer Biother. Radiopharm.* 18, 355–363.
- Boehm, J.S., Zhao, J.J., Yao, J., Kim, S.Y., Firestein, R., Dunn, I.F., Sjöström, S.K., Garraway, L.A., Weremowicz, S., Richardson, A.L., et al. (2007). Integrative genomic approaches identify *IKBKE* as a breast cancer oncogene. *Cell* 129, 1065–1079.
- Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., and Greenberg, M.E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96, 857–868.

- Carpenter, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 448, 439–444.
- Casamayor, A., Morrice, N.A., and Alessi, D.R. (1999). Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. *Biochem. J.* 342, 287–292.
- Currie, R.A., Walker, K.S., Gray, A., Deak, M., Casamayor, A., Downes, C.P., Cohen, P., Alessi, D.R., and Lucocq, J. (1999). Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. *Biochem. J.* 337, 575–583.
- Depowski, P.L., Rosenthal, S.I., and Ross, J.S. (2001). Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. *Mod. Pathol.* 14, 672–676.
- Dudek, H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R., and Greenberg, M.E. (1997). Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* 275, 661–665.
- Engelman, J.A., Luo, J., and Cantley, L.C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat. Rev. Genet.* 7, 606–619.
- Flynn, P., Wongdagger, M., Zavar, M., Dean, N.M., and Stokoe, D. (2000). Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. *Curr. Biol.* 10, 1439–1442.
- Frodin, M., Antal, T.L., Dummler, B.A., Jensen, C.J., Deak, M., Gammeltoft, S., and Biondi, R.M. (2002). A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. *EMBO J.* 21, 5396–5407.
- Garcia-Martinez, J.M., and Alessi, D.R. (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem. J.* 416, 375–385.
- Gould, J., Getz, G., Monti, S., Reich, M., and Mesirov, J.P. (2006). Comparative gene marker selection suite. *Bioinformatics* 22, 1924–1925.
- Gustin, J.P., Karakas, B., Weiss, M.B., Abukhdeir, A.M., Lauring, J., Garay, J.P., Cosgrove, D., Tamaki, A., Konishi, H., Konishi, Y., et al. (2009). Knockin of mutant *PIK3CA* activates multiple oncogenic pathways. *Proc. Natl. Acad. Sci. USA* 106, 2835–2840.
- Haruta, T., Uno, T., Kawahara, J., Takano, A., Egawa, K., Sharma, P.M., Olefsky, J.M., and Kobayashi, M. (2000). A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. *Mol. Endocrinol.* 14, 783–794.
- Hooshmand-Rad, R., Hajkova, L., Klint, P., Karlsson, R., Vanhaesebroeck, B., Claesson-Welsh, L., and Heldin, C.H. (2000). The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. *J. Cell Sci.* 113, 207–214.
- Isakoff, S.J., Engelman, J.A., Irie, H.Y., Luo, J., Brachmann, S.M., Pearline, R.V., Cantley, L.C., and Brugge, J.S. (2005). Breast cancer-associated *PIK3CA* mutations are oncogenic in mammary epithelial cells. *Cancer Res.* 65, 10992–11000.
- Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S.H., Zhang, J., Signoretti, S., Loda, M., Roberts, T.M., and Zhao, J.J. (2008). Essential roles of PI(3)K-p110 beta in cell growth, metabolism and tumorigenesis. *Nature* 454, 776–779.
- Jones, K.T., Greer, E.R., Pearce, D., and Ashrafi, K. (2009). Rictor/TORC2 regulates *Caenorhabditis elegans* fat storage, body size, and development through *sgk-1*. *PLoS Biol.* 7, e60.
- Kang, S., Bader, A.G., and Vogt, P.K. (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc. Natl. Acad. Sci. USA* 102, 802–807.
- King, C.C., and Newton, A.C. (2004). The adaptor protein Grb14 regulates the localization of 3-phosphoinositide-dependent kinase-1. *J. Biol. Chem.* 279, 37518–37527.
- Malo, N., Hanley, J.A., Cerquozzi, S., Pelletier, J., and Nadon, R. (2006). Statistical practice in high-throughput screening data analysis. *Nat. Biotechnol.* 24, 167–175.
- Miller, S.J., Xing, X., Xi, L., and Hung, M.C. (1996). Identification of a specific DNA region required for enhanced transcription of *HER2/neu* in the MDA-MB453 breast cancer cell line. *DNA Cell Biol.* 15, 749–757.
- Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepper, A.M., Hinkle, G., Piquani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 124, 1283–1298.
- Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M., and Sellers, W.R. (2000). Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. *Mol. Cell. Biol.* 20, 8969–8982.
- Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 10, 515–527.
- O'Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L., et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res.* 66, 1500–1508.
- Oda, K., Stokoe, D., Taketani, Y., and McCormick, F. (2005). High frequency of coexistent mutations of *PIK3CA* and *PTEN* genes in endometrial carcinoma. *Cancer Res.* 65, 10669–10673.
- Saal, L.H., Johansson, P., Holm, K., Gruvberger-Saal, S.K., She, Q.B., Maurer, M., Koujak, S., Ferrando, A.A., Malmstrom, P., Memeo, L., et al. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proc. Natl. Acad. Sci. USA* 104, 7564–7569.
- Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. (2004). High frequency of mutations of the *PIK3CA* gene in human cancers. *Science* 304, 554.
- Samuels, Y., Diaz, L.A., Jr., Schmidt-Kittler, O., Cummins, J.M., Delong, L., Cheong, I., Rago, C., Huso, D.L., Lengauer, C., Kinzler, K.W., et al. (2005). Mutant *PIK3CA* promotes cell growth and invasion of human cancer cells. *Cancer Cell* 7, 561–573.
- Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 307, 1098–1101.
- Serunian, L.A., Auger, K.R., and Cantley, L.C. (1991). Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. *Methods Enzymol.* 198, 78–87.
- She, Q.B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K.M., Leander, K.R., DeFeo-Jones, D., Huber, H.E., and Rosen, N. (2008). Breast tumor cells with PI3K mutation or *HER2* amplification are selectively addicted to Akt signaling. *PLoS ONE* 3, e3065.
- Slagsvold, T., Marchese, A., Brech, A., and Stenmark, H. (2006). CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4. *EMBO J.* 25, 3738–3749.
- Solit, D.B., Garraway, L.A., Pratils, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 439, 358–362.
- Soukas, A.A., Kane, E.A., Carr, C.E., Melo, J.A., and Ruvkun, G. (2009). Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in *Caenorhabditis elegans*. *Genes Dev.* 23, 496–511.
- Stemke-Hale, K., Gonzalez-Angulo, A., Lluch, A., Neve, R.M., Davies, M.A., Carey, M., Sahin, A., Symmans, W.F., Pusztai, L., Nolden, L.K., et al. (2008). An integrative genomic and proteomic analysis of *PIK3CA*, *PTEN* and *AKT* mutations in breast cancer. *Cancer Res.* 68, 6084–6091.
- Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G.F., Holmes, A.B., Gaffney, P.R., Reese, C.B., McCormick, F., Tempst, P., et al. (1998). Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. *Science* 279, 710–714.
- Stinson, S.F., Alley, M.C., Kopp, W.C., Fiebig, H.H., Mullendore, L.A., Pittman, A.F., Kenney, S., Keller, J., and Boyd, M.R. (1992). Morphological and

- immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. *Anticancer Res.* **12**, 1035–1053.
- Tessier, M., and Woodgett, J.R. (2006). Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. *J. Biol. Chem.* **281**, 23978–23989.
- Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., and Kornblau, S.M. (2006). Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. *Mol. Cancer Ther.* **5**, 2512–2521.
- Torbett, N.E., Luna, A., Knight, Z.A., Houk, A., Moasser, M., Weiss, W., Shokat, K.M., and Stokoe, D. (2008). A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. *Biochem. J.* **415**, 97–110.
- Vanhaesebroeck, B., and Alessi, D.R. (2000). The PI3K-PDK1 connection: more than just a road to PKB. *Biochem. J.* **346**, 561–576.
- Vanhaesebroeck, B., Leever, S.J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P.C., Woscholski, R., Parker, P.J., and Waterfield, M.D. (2001). Synthesis and function of 3-phosphorylated inositol lipids. *Annu. Rev. Biochem.* **70**, 535–602.
- Varnai, P., and Balla, T. (1998). Visualization of phosphoinositides that bind pleckstrin homology domains: calcium- and agonist-induced dynamic changes and relationship to myo-[³H]inositol-labeled phosphoinositide pools. *J. Cell Biol.* **143**, 501–510.
- Virbasius, J.V., Song, X., Pomerleau, D.P., Zhan, Y., Zhou, G.W., and Czech, M.P. (2001). Activation of the Akt-related cytokine-independent survival kinase requires interaction of its phox domain with endosomal phosphatidylinositol 3-phosphate. *Proc. Natl. Acad. Sci. USA* **98**, 12908–12913.
- Vivanco, L., and Sawyers, C.L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat. Rev. Cancer* **2**, 489–501.
- Watton, S.J., and Downward, J. (1999). Akt/PKB localisation and 3' phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. *Curr. Biol.* **9**, 433–436.
- Xu, J., Liao, L., Qin, J., Xu, J., Liu, D., and Songyang, Z. (2009). Identification of flightless-I as a substrate of the cytokine-independent survival kinase CISK. *J. Biol. Chem.* **284**, 14377–14385.
- Zeng, X., Xu, H., and Glazer, R.I. (2002). Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. *Cancer Res.* **62**, 3538–3543.
- Zhang, L., Bewick, M., and Lafrenie, R.M. (2002). EGFR and ErbB2 differentially regulate Raf-1 translocation and activation. *Lab. Invest.* **82**, 71–78.
- Zhao, J.J., Liu, Z., Wang, L., Shin, E., Loda, M.F., and Roberts, T.M. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc. Natl. Acad. Sci. USA* **102**, 18443–18448.